Collegium Pharmaceutical Future Growth
Future criteria checks 4/6
Collegium Pharmaceutical's revenue is forecast to decline at 6.8% per annum while its annual earnings are expected to grow at 25.4% per year. EPS is expected to grow by 23% per annum. Return on equity is forecast to be 41.6% in 3 years.
Key information
25.4%
Earnings growth rate
23.0%
EPS growth rate
Pharmaceuticals earnings growth | 20.6% |
Revenue growth rate | -6.8% |
Future return on equity | 41.6% |
Analyst coverage | Good |
Last updated | 27 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 565 | 174 | N/A | 340 | 5 |
12/31/2025 | 596 | 144 | 311 | 328 | 6 |
12/31/2024 | 584 | 116 | 292 | 346 | 6 |
12/31/2023 | 567 | 48 | 274 | 275 | N/A |
9/30/2023 | 547 | 9 | 266 | 268 | N/A |
6/30/2023 | 537 | -11 | 235 | 236 | N/A |
3/31/2023 | 525 | -29 | 176 | 177 | N/A |
12/31/2022 | 464 | -25 | 123 | 124 | N/A |
9/30/2022 | 362 | -43 | 93 | 94 | N/A |
6/30/2022 | 314 | -35 | 67 | 69 | N/A |
3/31/2022 | 273 | 43 | 56 | 58 | N/A |
12/31/2021 | 277 | 72 | 102 | 104 | N/A |
9/30/2021 | 326 | 104 | 87 | 90 | N/A |
6/30/2021 | 326 | 107 | 102 | 107 | N/A |
3/31/2021 | 321 | 42 | 115 | 121 | N/A |
12/31/2020 | 310 | 27 | -280 | 94 | N/A |
9/30/2020 | 308 | 18 | -286 | 87 | N/A |
6/30/2020 | 302 | 0 | -313 | 59 | N/A |
3/31/2020 | 299 | -13 | -341 | 30 | N/A |
12/31/2019 | 297 | -23 | 21 | 28 | N/A |
9/30/2019 | 296 | -11 | 47 | 54 | N/A |
6/30/2019 | 293 | -22 | 81 | 90 | N/A |
3/31/2019 | 291 | -30 | 123 | 131 | N/A |
12/31/2018 | 280 | -39 | 145 | 169 | N/A |
9/30/2018 | 218 | -66 | 91 | 114 | N/A |
6/30/2018 | 160 | -62 | 39 | 59 | N/A |
3/31/2018 | 90 | -70 | -34 | -14 | N/A |
12/31/2017 | 28 | -75 | -68 | -67 | N/A |
9/30/2017 | 19 | -85 | N/A | -77 | N/A |
6/30/2017 | 7 | -98 | N/A | -84 | N/A |
3/31/2017 | 4 | -102 | N/A | -87 | N/A |
12/31/2016 | 2 | -94 | N/A | -75 | N/A |
9/30/2016 | 0 | -76 | N/A | -61 | N/A |
6/30/2016 | N/A | -59 | N/A | -48 | N/A |
3/31/2016 | N/A | -40 | N/A | -31 | N/A |
12/31/2015 | N/A | -20 | N/A | -22 | N/A |
9/30/2015 | N/A | -15 | N/A | -20 | N/A |
6/30/2015 | N/A | -13 | N/A | -18 | N/A |
3/31/2015 | N/A | -12 | N/A | -16 | N/A |
12/31/2014 | N/A | -21 | N/A | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 354's forecast earnings growth (25.4% per year) is above the savings rate (0.6%).
Earnings vs Market: 354's earnings (25.4% per year) are forecast to grow faster than the German market (15.1% per year).
High Growth Earnings: 354's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 354's revenue is expected to decline over the next 3 years (-6.8% per year).
High Growth Revenue: 354's revenue is forecast to decline over the next 3 years (-6.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 354's Return on Equity is forecast to be very high in 3 years time (41.6%).